A new multi-stakeholder consensus roadmap is pushing to streamline clinical trials for rare childhood CNS tumors, where the traditional bottleneck has been that trial infrastructure struggles to keep pace with emerging science. Published in the British Journal of Cancer, the document proposes a strategic blueprint for making trials more practical and more inclusive. The roadmap is positioned as a response to a structural issue: trial designs, eligibility criteria, and enrollment pathways often fail to match the small patient populations and biological heterogeneity typical of pediatric CNS malignancies. For investigators and sponsors, the central emphasis is on how to coordinate trial operations—such as site selection, harmonization of endpoints, and inclusive eligibility—so that new therapies can be tested more efficiently. In the broader pediatric oncology ecosystem, the consensus framework is likely to influence trial sponsors’ operational planning and regulatory engagement by standardizing expectations around feasibility and inclusivity for rare disease studies.